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Shank family proteins (Shank1, Shank2, and Shank3) are synaptic scaffolding proteins that organize an
extensive protein complex at the postsynaptic density (PSD) of excitatory glutamatergic synapses. Recent
human genetic studies indicate that SHANK family genes (SHANK1, SHANK2, and SHANK3) are causative
genes for idiopathic autism spectrum disorders (ASD). Neurobiological studies of Shank mutations in mice
support a general hypothesis of synaptic dysfunction in the pathophysiology of ASD. However, themolecular
diversity of SHANK family gene products, as well as the heterogeneity in human and mouse phenotypes,
pose challenges to modeling human SHANK mutations. Here, we review the molecular genetics of SHANK
mutations in human ASD and discuss recent findings where such mutations have been modeled in mice.
Conserved features of synaptic dysfunction and corresponding behaviors in Shank mouse mutants may
help dissect the pathophysiology of ASD, but also highlight divergent phenotypes that arise from different
mutations in the same gene.Introduction
In recent years, tremendous progress has been made in recog-
nizing and diagnosing autism, a condition that was first
described by Kanner and Asperger nearly 70 years ago (As-
perger, 1944; Kanner, 1943; Volkmar et al., 2009). Clinically,
autistic phenotypes are present in a group of heterogeneous
conditions, termed autism spectrum disorders (ASD) (Lord
et al., 2000a). Genetic risk contributes significantly to idiopathic
ASD, but the specific genetic alterations remain elusive in the
majority of cases (Abrahams and Geschwind, 2008; Folstein
and Rosen-Sheidley, 2001; State, 2010b). Remarkably little is
known about the underlying pathophysiology or neurological
basis of ASD (Amaral et al., 2008; Courchesne et al., 2007;
Geschwind and Levitt, 2007; Rubenstein, 2010; Zoghbi, 2003).
The development of animal models is an important step in
bridging the human genetics of ASD to circuit-based deficits un-
derlying the clinical presentation, and ultimately to discovering,
designing, and deploying effective therapeutic strategies.
SHANK/ProSAP family proteins (SHANK1, SHANK2,
SHANK3) have emerged as promising candidates for modeling
ASD in mice due to strong genetic evidence showing molecular
defects of SHANK in patients with ASD (Berkel et al., 2010, 2012;
Durand et al., 2007; Gauthier et al., 2010; Marshall et al., 2008;
Pinto et al., 2010; Sato et al., 2012). Mutations of SHANK3
were the first (Durand et al., 2007) and remain the best character-
ized SHANK mutations in human ASD (Boccuto et al., 2013;
Moessner et al., 2007). Recently, mutations in SHANK1 and
SHANK2 have also been associated with ASD (Berkel et al.,
2010, 2012; Sato et al., 2012), supporting a general function for
this gene family in common molecular pathways associated
with ASD. Shank family proteins are scaffolding proteins that
organize a cytoskeleton-associated signaling complex at the
postsynaptic density (PSD) of nearly all excitatory glutamatergic
synapses in the mammalian brain (Grabrucker et al., 2011b;
Gundelfinger et al., 2006; Kreienkamp, 2008; Sheng and Kim,
2000). The genetic association of ASD with SHANK family genes8 Neuron 78, April 10, 2013 ª2013 Elsevier Inc.provided an immediate link between synaptic dysfunction and
the pathophysiology of ASD. Shank1 mutant mice were first re-
ported in 2008 (Hung et al., 2008). Recently, two Shank2
(Schmeisser et al., 2012; Won et al., 2012) and five Shank3
mutant mice have been reported (Bozdagi et al., 2010; Pec¸a
et al., 2011; Schmeisser et al., 2012; Wang et al., 2011). Analysis
of these mutant mice has yielded a wealth of new information
and raised numerous questions. Here, we compare and contrast
the various Shank mouse models with a focus on Shank3,
discuss the potential relevance to human ASD, and highlight
key challenges and opportunities in studying the role of SHANK
genes in ASD.
Genetic Linkage of SHANK Genes to Autism Spectrum
Disorders
In humans, SHANK3 is one of the best characterized genes
implicated in ASD. SHANK3 maps to the critical region of
22q13.3 deletion syndrome (Phelan-McDermid syndrome,
PMS) (Figure 1A; Wilson et al., 2003). The key clinical features
associatedwith PMSare global developmental delay, hypotonia,
absent or severely delayed language, autistic behaviors, and
intellectual disability (Phelan, 2007). Atypical bipolar disorder
has also been associated with 22q13.3 deletions in recent
case reports (Denayer et al., 2012; Verhoeven et al., 2012,
2013). The size of the deletions in PMS is extremely variable
(0.1–10 Mb) (Dhar et al., 2010; Wilson et al., 2003), but deletions
of SHANK3 have been reported in all cases except in one report
of two children who have deletions proximal to SHANK3 (Wilson
et al., 2008), suggesting that other genes in 22q13.3 may also be
important for brain function. Much smaller deletions specific to
SHANK3 or balanced translocations within the SHANK3 gene
have been reported in patients with neurobehavioral features
indistinguishable from patients with large deletions including
SHANK3 (Anderlid et al., 2002; Bonaglia et al., 2006; Wong
et al., 1997). These observations have led to the conclusion
that haploinsufficiency of SHANK3 is a major contributor to the
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quently, point mutations and microdeletions of SHANK3 have
been identified in idiopathic ASD cases (Boccuto et al., 2013;
Dhar et al., 2010; Durand et al., 2007; Gauthier et al., 2010;
Gong et al., 2012; Marshall et al., 2008; Moessner et al., 2007;
Waga et al., 2011). In all, six types of molecular defects have
been identified in SHANK3 in more than 1000 human patients.
These include (1) cytogenetically visible terminal deletion of
22q13.3 or ring chromosome of 22 (Jeffries et al., 2005; Wilson
et al., 2003), (2) a microdeletion detected by array-based
methods (Boccuto et al., 2013; Dhar et al., 2010), (3) micro-
duplication (Okamoto et al., 2007), (4) translocations with break-
points within the SHANK3 gene (Bonaglia et al., 2006), (5) small
intragenic deletions (Bonaglia et al., 2011), and (6) point muta-
tions (Boccuto et al., 2013; Durand et al., 2007; Moessner
et al., 2007).
De novo sequence changes in SHANK3 including missense,
frame shift, and splice site mutations have been reported
in ASD patients (Boccuto et al., 2013; Durand et al., 2007; Gauth-
ier et al., 2010; Gauthier et al., 2009; Gong et al., 2012; Hamdan
et al., 2011; Moessner et al., 2007; Schaaf et al., 2011; Waga
et al., 2011). The positions of these point mutations that are likely
pathological are depicted in Figure 1A, and themajor clinical fea-
tures extracted from case reports are summarized in Table 1.
Point mutations affecting the splice acceptor site in intron 5
(Hamdan et al., 2011) and splice donor site of intron 19 (Gauthier
et al., 2009), as well as a one base pair insertional mutation in
exon 21 causing a frame shift (p.A1227fs) (Durand et al., 2007),
were found in children with ASD and severe speech delay. The
p.A447fs mutation was found in a child with atypical autism dis-
order and speech delay. This mutation was inherited from his fa-
ther who also exhibits learning disability and attention deficit hy-
peractivity disorder (Boccuto et al., 2013). In contrast, a splice
mutation of c.1820-4G > A is associated with a child with mild
ASD (Asperger syndrome) (Boccuto et al., 2013). Intellectual
disability was mild in the patient with the intron 5 splicing muta-
tion (Hamdan et al., 2011), severe in the patient with the
p.A1227fs exon 21 mutation (Durand et al., 2007), and was not
described in the patient with the intron 19 splice mutation
(Gauthier et al., 2009). The p.E1331fs mutation, which is in the
last coding exon close to stop codon, was found in children
with pervasive developmental disorder not otherwise specified
(PDD-NOS) and severe intellectual disability (Boccuto et al.,
2013). Several small intragenic or interstitial deletions have
also been reported (Bonaglia et al., 2011). Intragenic deletions
of exons 1–9 or exons 1–17 of SHANK3 have been found in pa-
tients exhibiting severe language delay and significant intellec-
tual disability, but a formal evaluation for ASDwas not performed
in these two cases (Bonaglia et al., 2011). Together, these data
strongly support a conclusion that molecular defects of SHANK3
can cause ASD but with variable presentations. However, the
frequency of putatively pathological mutations in SHANK3 ap-
pears to be rare in ASD (<0.75%) (Moessner et al., 2007), and
the degree to which SHANK3mutations contribute to the popu-
lation attributable risk of ASD is small (Betancur, 2011; Bux-
baum, 2009; State, 2010b). Many missense mutations have
been identified in SHANK3 (Gauthier et al., 2009; Moessner
et al., 2007; Schaaf et al., 2011), but their clinical relevance hasnot been determined. Although the number of cases with point
mutations that are clearly pathological in nature is still small,
the clinical features from these cases reports suggest a geno-
type-phenotype correlation related to the autism diagnosis.
Interestingly, point mutations, including a nonsense mutation in
exon 21 (p.R1117X) of SHANK3 have been reported in families
with schizophrenia and mild intellectual disability (Gauthier
et al., 2010). This observation is consistent with recent reports
that similar copy number variants (CNVs) are found across
many genomic loci in both ASD and schizophrenia (Cook and
Scherer, 2008; Gejman et al., 2011; Moreno-De-Luca et al.,
2010; Sanders et al., 2011). Microduplications of SHANK3
have also been reported in children with developmental delay
and dysmorphic features (Okamoto et al., 2007), suggesting
that SHANK3 gene dosage affects brain function.
More recently, point mutations ofSHANK2 andmicrodeletions
of SHANK1 and SHANK2 have been found in patients with ASD
and intellectual disability (Figures 1B and 1C; Berkel et al., 2010;
Leblond et al., 2012; O’Roak et al., 2012; Pinto et al., 2010; Sato
et al., 2012). Compared to SHANK3, the number of cases with
SHANK2 mutations is small but convincing. All microdeletions
found in ASD are intragenic deletions that disrupt the SHANK2
protein. A nonsense mutation in SHANK2 exon 24 encoding
the proline-rich homer-binding domain has also been found in
an ASD proband (Figure 1B; Berkel et al., 2010). Mutations of
SHANK3 at similar location were also found in ASD (Boccuto
et al., 2013; Durand et al., 2007). In the case of SHANK1, micro-
deletions including SHANK1 and two other adjacent genes were
reported in five ASD individuals in two families with mild ASD
(Figure 1C). Pathological point mutations have not yet been re-
ported in ASD (Sato et al., 2012).
To date, correlation between genotype and phenotype has
been described in patients with 22q13.3 deletions including
SHANK3 (Sarasua et al., 2011). In most reports, clinical features
were described by self-reporting or extracted from existingmed-
ical records. A summary of the molecular and clinical finding
related to SHANK3 variants is provided in Table 1 based on
the available data from individual reports in the literature (Boc-
cuto et al., 2013; Bonaglia et al., 2011; Dhar et al., 2010; Gauthier
et al., 2009, 2010; Moessner et al., 2007; Philippe et al., 2008;
Sarasua et al., 2011; Waga et al., 2011; Wilson et al., 2003).
Importantly, the quality of clinical data varies and is often incom-
plete in these reports and thus direct comparisons should be
madewith caution. Diagnostic evaluations for ASDwere not con-
ducted in themajority of cases or were carried out using different
evaluation protocols. Because the clinical data are not complete
in most cases, it is difficult to draw firm conclusions about the
relationship between specific SHANK3 variants and clinical fea-
tures related to ASD. This challenge is best illustrated in three
cases with very similar mutations (p.A1227fs, p.E1311fs, and
p.R1117X) in exon 21 encoding the proline-rich Homer binding
site of SHANK3 (Figure 1A). Mutations p.A1227fs and
p.E1331fs were found in patients with ASD or PDD-NOS, severe
language delay, and significant intellectual disability (Boccuto
et al., 2013; Durand et al., 2007), while p.R1117X was found in
patients with schizophrenia and mild intellectual disability
(Gauthier et al., 2010). Similarly, in other cases with almost
identical small microdeletions (<100 kb) including SHANK3,Neuron 78, April 10, 2013 ª2013 Elsevier Inc. 9
Figure 1. SHANK Mutations Causing Autism-Related Phenotypes
(A)SHANK3 is part of a large gene cluster associatedwith deletions in chromosome 22q13.3 deletion syndrome, or Phelan-McDermid syndrome, associated with
autistic behaviors and intellectual disability (select genes are shown). The deletion sizes vary from 17 kb within SHANK3 to 10 Mb in 22q13.3. SHANK3 gene
structure, mutations, and protein domains are shown. Human SHANK3 has 23 exons as deduced from cDNA AB569469 deposited in GenBank. Exon 11a is a
(legend continued on next page)
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2013; Bonaglia et al., 2011; Dhar et al., 2010). One hypothesis to
explain these differences is the presence of a genetic or epige-
netic variant in the other allele of SHANK3, or haploinsufficiency
and positional effects of deletions on other genes known to
cause autosomal-recessive neurological disorders in the
22q13.3 region. For example, genes implicated in metachro-
matic leukodystrophy (ARSA), congenital disorders of glycosyla-
tion (ALG12), and spinocerebellar ataxia type 10 (ATXN10) are
mapped within the 22q13.3 region. In addition, mutations or
allelic variation in as-yet-unidentified genes that function as
epistatic modifiers for SHANK3 could influence the phenotypes
associated with SHANK3 defects.
In the cases of SHANK1 and SHANK2 mutations associated
with ASD, no studies relating genotype and phenotype have
been reported. The penetrance of SHANK2 mutations in ASD
is not complete in some cases (Leblond et al., 2012). This obser-
vation has led to the proposal of a multiple hit model to explain
the clinical relevance of SHANK2 mutations. Because the num-
ber of ASD cases with two genetic hits including SHANK2 is
small, the validity of the model remains to be tested in additional
patient cohorts or by functional studies. Interestingly, micro-
deletion of SHANK1 is only penetrant in males with mild ASD
in families studied (Sato et al., 2012). The molecular basis for
gender-specific penetrance related to SHANK1 mutations is
not immediately clear but may provide an opportunity to investi-
gate mechanisms underlying higher male gender-specific risk
in ASD.
Deletions involving entire SHANK family genes in ASD predict
that haploinsufficiency is the primary mechanism underlying
ASD pathogenesis (Wilson et al., 2003). By comparison, for point
mutations such as missense mutation and small intragenic dele-
tions identified in SHANK2 and SHANK3, the pathogenic mech-
anism is less clear (Bonaglia et al., 2011; Durand et al., 2012;
Moessner et al., 2007). The possibility of gain-of-function or
dominant-negative effects in addition to loss-of-function should
be considered if mutated mRNA transcripts produce stable
mutated or truncated proteins. Different SHANK mutations
may thus act through different mechanisms to alter protein-pro-
tein interactions at the PSD and cause synaptic dysfunction that
may underlie clinical presentations of disorder. However, to
date, we have little information on the molecular mechanisms
bywhichmore subtlemutations inSHANK3 alter protein function
at synapses (Durand et al., 2007, 2012).newly identified exon. The positions of six identified promoters are indicated as
mutations are indicated as blue arrows and the nature of point mutations are as d
et al., 2011), p.Q312R in exon 8 (Moessner et al., 2007), p.G440_P446 del and p
splicing mutation in intron 15 (Boccuto et al., 2013), p.R656H in exon 16 (Waga e
and p.R1117X, p.A1227fs, p.E1311fs in exon 21 (Boccuto et al., 2013; Durand e
corresponding exons (ANK, ankyrin repeat domain; SH3, Src homology 3 domain
homer- and cortactin-binding sites; SAM, sterile alpha motif domain). CpG island
(B) SHANK2 gene structure, protein domains, isoforms, microdeletions and mutat
in ASD are intragenic and within the SHANK2 genomic region. Point mutations
described above the arrow. Three identifiable promoters corresponding to SHANK
indicated as yellow arrows.
(C) SHANK1 gene structure, protein domains, isoforms, and microdeletions in AS
pathological point mutations in SHANK1 have been reported in ASD. The positio
isoforms have not been fully characterized.
In (A)–(C), genomic distance and exons are not drawn to scale.SHANK Encodes a Multidomain Scaffolding Protein
Present at Glutamatergic Synapses
Shank/ProSAP family members including Shank3 have five
conserved protein domains—an ankyrin repeat domain (ANK),
Src homology 3 (SH3) domain, a PSD-95/Discs large/ZO-1
(PDZ) domain, a proline-rich region containing homer- and cor-
tactin-binding sites (Pro), and a sterile alpha motif (SAM) domain
(Figure 2A). Shanks are scaffolding proteins that interact with
many synaptic proteins in the PSD (Ehlers, 1999; Gundelfinger
et al., 2006; Kreienkamp, 2008; Sheng and Kim, 2000). More
than 30 synaptic proteins have been reported to interact with
Shank family proteins (Figure 2 and Table 2). Due to the similarity
of protein domains among Shank family proteins, in vitro binding
experiments have shown a significant overlap in protein-protein
interactions involving Shank1-3. Shank3-interacting proteins
include receptors, ion channels, cytoskeletal proteins, scaf-
folding proteins, enzymes, and signaling molecules (Grabrucker
et al., 2011b; Kreienkamp, 2008). The large protein complex
organized by Shanks performs a variety of functions at the
postsynaptic membrane including actin-based cytoskeletal
remodeling, synapse formation, AMPA receptor endocytosis,
and regulation of synaptic transmission and plasticity (Table 2).
Whether all these protein-protein interactions occur in vivo are
unknown and the precise function for these interactions remains
to be fully elucidated.
Concentrated at glutamatergic synapses, Shanks interact
directly or indirectly with all major types of glutamate recep-
tors—NMDA receptors, AMPA receptors, and mGluRs—via
different domains (Ehlers, 1999; Naisbitt et al., 1999; Tu et al.,
1999; Uchino et al., 2006; Verpelli et al., 2011). When overex-
pressed in cultured neurons from mice, Shanks recruit GluA1
AMPA receptors and increases the formation of new synapses
(Roussignol et al., 2005). Expression of Shank3 with deletions
of various domains in cultured mouse neurons has demon-
strated distinct roles for each domain in dendritic spine develop-
ment (Roussignol et al., 2005). For example, mutation of the PDZ
domain of Shank3 results in a reduction in dendritic spine forma-
tion while mutation of ANK-SH3 domains leads to spines with
normal length but reduced spine head area. In contrast, mutation
in the cortactin binding site results in longer spines with reduced
spine head area (Roussignol et al., 2005).
At present, it is unclear how the interactions of Shanks with
various glutamate receptor subtypes are coordinated and regu-
lated at a given synapse. In cultured rat neurons, knock-down ofblack arrows. The exons in red are alternatively spliced. The positions of point
escribed above the arrow. c.601-1G > A splicing mutation in intron 5 (Hamdan
.A447fs in exon 11 (Boccuto et al., 2013; Waga et al., 2011), c.1820-4 G > A
t al., 2011), c.2265+1 delG splicing mutation in intron 19 (Gauthier et al., 2009),
t al., 2007; Gauthier et al., 2010). Protein domains are shown and aligned to
; PDZ, PSD-95/Discs large/ZO-1 domain; Pro, a proline-rich region containing
s are sites of differential methylation and are indicated by green bars.
ions in ASD. Exons in red are alternatively spliced exons. Microdeletions found
found in ASD are indicated as blue arrows and the nature of mutations are
2E, 2A, 2B are indicated as black arrow. Two alternative stop codons (TAA) are
D. Two small deletions including SHANK1 and two other genes are shown. No
ns for two promoters are shown (Lim et al., 1999). The alternative splicing and
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Table 1. Genotype/Phenotype Correlations of Human SHANK3 Mutations
Genetic Defect
No. of
Case
SHANK3
Isoforms
Affected
Other
Genes
Disrupted
ASD-Related
Diagnosis
Intellectual
Disability (ID) Other Clinical Features
22q13.3 deletion
(including SHANK3)
(0.1-10Mb)
>1000 All isoforms
disrupted
From 2-30
other genes
ASD diagnosis
in >75% of cases
>95% cases with
developmental delay,
moderate to severe
ID, absent speech, or
severe speech delay
Hypotonia, seizure,
motor development
delay, facial
dysmorphism,
increased pain
threshold, bipolar
disorder, mild
congenital anomaly
Microdeletion
of SHANK3
3 All isoforms
disrupted
None or /
ACR
ASD Speech delay
and mild ID
Hyperactivity,
hypospadias,
behavioral issues,
seizure/regression
Intragenic deletion
Deletion size
Exons/domain
deleted
38 kb exon 1–9 ANK 1 SHANK3a/b none Not mentioned Moderate ID, profound
delay in language
acquisition
Microcephaly,
astigmatism
74 kb exon 1–17 ANK/
SH3/PDZ
1 SHANK3a-e none Not evaluated Profound ID Mild congenital
anomalies
44 kb Exon 19–23
Homer
binding/SAM
1 SHANK3f ACR ASD Moderate
ID/hyperactivity
disorder
Short stature, facial
dysmorphism,
astigmatism
27 kb exon 20–23
Homer binding/
SAM
1 SHANK3f ACRa Classical autism Not mentioned ADHD, no facial
dysmorphism
17 kb Exon 23
SAM
1 SHANK3f ACR No ASD by
CARS and ABC
Mild ID, severe delay
in language acquisition
Mild facial
dysmorphism,
mild motor delay
Point mutation/Small deletion
Mutation
Exon/protein
domain 1
c.601-1G > A ANK 1 SHANK3a-b None No ASD Mild ID, severe
language impairment
p.Q312Rb Exon 8
ANK
1 SHANK3a-b None ASD by ADI-R
and ADOS
language delay Abnormal EEG but
no seizures; has self-
injurious behavior
p.A447fsc Exon 11
SH3
1 SHANK3a-c None Borderline score
for ASD evaluation
Language delay No facial dysmorphism
p.G440_P446 del Exon 11
SH3
1 SHANK3a-c None ASD Severe ID Delayed psychomotor
development
c.1820-4G > A PDZ 1 SHANK3a-d None Asperger’s
syndrome
Normal speech and
some behavioral
problems
Facial dysmorphism/
mild congenital
anomaly
p.R656Hd Exon 16
PDZ
1 SHANK3a-d None ASD Mild ID, development
delay
c.2265+1 del G 1 SHANK3a-e None ASD Not mentioned
p.R1117X Exon 21
Homer binding
1 SHANK3f None No evidence
for ASD
Mild to moderate ID Schizophrenia,
hyperactivity/no facial
dysmorphism
p.A1227fs Exon 21
Homer-binding
1 SHANK3f None ASD Severe ID and
impaired speech
(Continued on next page)
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Table 1. Continued
Genetic Defect
No. of
Case
SHANK3
Isoforms
Affected
Other
Genes
Disrupted
ASD-Related
Diagnosis
Intellectual
Disability (ID) Other Clinical Features
p.E1311fs Exon 21
Homer-binding
1 SHANK3f None PDD-NOS Severe ID and
absent speech
Seizure, facial
dysmorphism, motor
development delay
The information in the table is extracted from following reports: Boccuto et al., 2013; Bonaglia et al., 2011; Dhar et al., 2010; Durand et al., 2007; Gauth-
ier et al., 2009, 2010; Moessner et al., 2007; Phelan, 2007; Sarasua et al., 2011; Waga et al., 2011;Wilson et al., 2003;Wong et al., 1997). ACR, Acrosin,
a sperm specific proteinase which has no known function in brain; ABC, autism behavioral checklist; ADHD, attention deficit-hyperactivity disorder;
ADI-R, autism diagnosis interview-revised; ADOS, autism diagnosis observation scale; CARS, child autism rating scale; Del, deletion; EEG, electro-
encephalography; ID, intellectual disability; PDD-NOS, pervasive developmental disorder-otherwise not specified.
aProband has a chromosome 9p24.3 copy number gain that is inherited from mother and considered a benign variant.
bParents are first cousins.
cThe variant is inherited from father who has learning disability and attention deficit disorder.
dVariant is also found in healthy and normal father.
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pairs mGluR5-dependent signaling and plasticity (Verpelli
et al., 2011). Whether similar deficits are present in vivo is not
yet clear, although excessive mGluR5 signaling has been impli-
cated in fragile X syndrome (Krueger and Bear, 2011), which
has clinical overlap with 22q13.3 deletions (Phelan, 2008).
Among the various Shank binding proteins, Homer family mem-
bers have been shown to regulate diverse synaptic functions
(Hayashi et al., 2009; Sala et al., 2001; Tu et al., 1999). Homer1
and Shank1 form a mesh-like matrix that is thought to function
as an organizing lattice for PSD proteins (Hayashi et al., 2009).
Shank3 shares very similar protein domain structure to Shank1,
suggesting that Shank3 participates in a similar protein network
with Homer1. As with interactions involving glutamate receptors,
it is not yet known how the multitude of Shank interactions with
other scaffolding and signaling proteins at a given synapse are
coordinated and regulated.
Shank3 shares a similar protein domain structure but has a
different expression pattern and subcellular localization than
Shank1 and Shank2 (Bo¨ckers et al., 2004; Pec¸a et al., 2011;
Tao-Cheng et al., 2010). Shank3 forms multimers via its C-termi-
nal SAM domain (Boeckers et al., 2005; Hayashi et al., 2009;
Naisbitt et al., 1999) as well as its PDZ domain (Iskenderian-
Epps and Imperiali, 2010). The SAM domain of Shank3 has a
Zn2+ binding site that is important for Shank3 protein folding
at the PSD as well as for synaptogenesis and synapse matura-
tion in vitro (Baron et al., 2006; Grabrucker et al., 2011a).
Biochemically, Shank family proteins are ubiquitinated in an ac-
tivity-dependent manner in neurons (Ehlers, 2003). The exact
biochemical mechanism responsible the ubiquitination of Shank
family protein remains to be determined. Many interesting
questions related to the molecular function of Shank3 await
further investigation. Does Shank3 interact with different pro-
teins in a synapse-specific manner? Is the interaction of Shank3
with synaptic proteins regulated by activity? How do these inter-
actions and post-translational modifications contribute to the
synaptic defects in human ASD and intellectual disability associ-
ated with the SHANK3 defects? Because point mutations and
microdeletions in similar domains of SHANK1 and SHANK2
have been reported in ASD (Berkel et al., 2010; Pinto et al.,
2010; Sato et al., 2012), an interesting question is do variousSHANKmutations cause ASD by disrupting similar mechanisms
at the synapse (State, 2010a)?
Molecular Diversity of SHANK Gene Products
SHANK genes display a complex transcriptional regulation
with multiple intragenic promoters and extensive alternatively
spliced exons both in humans and mice (Leblond et al., 2012;
Lim et al., 1999; Maunakea et al., 2010; McWilliams et al.,
2004; Redecker et al., 2006; Wang et al., 2011; Wilson et al.,
2003). Transcripts of SHANK3 are the best characterized among
the three family members in human and mice (Durand et al.,
2007;Maunakea et al., 2010;Wang et al., 2011). The alternatively
spliced exons of Shank3 encode the SH3, proline-rich, and SAM
domains (Figure 1A). Combinations of multiple intragenic pro-
moters and alterative splicing result in an extensive array of
mRNA and deduced protein isoforms. The exact number of pro-
tein isoforms has not been determined, but selected mRNA iso-
forms analyzed in silico indicate that each Shank3 isoform
(Shank3a-f) has a unique combination of different protein do-
mains as illustrated in Figure 2B (Wang et al., 2011). For example,
Shank3e and Shank3f mRNAs lack exons encoding the PDZ
domain that is responsible for the interaction with NMDA and
AMPA receptors (Naisbitt et al., 1999). Shank3b lacks the pro-
line-rich and SAM domains that are critical for Homer binding
and multimerization (Tu et al., 1999). Because each protein
domain mediates a unique complement of protein-protein inter-
actions (Hayashi et al., 2009; Roussignol et al., 2005), it is likely
that each Shank3 isoform has a distinct set of functions. An
important area for future research will be to determine the func-
tion for each isoform in vivo and its relevance to synaptic and
behavioral phenotypes. The diversity of SHANK3 isoforms may
contribute to synaptic signaling and postsynaptic protein
composition. In addition, since Shank3 mRNA has been found
in dendrites (Bo¨ckers et al., 2004), the specific Shank3 mRNAs
targeted to dendrites or perhaps individual synapses may also
be isoform specific.
The complexity of SHANK3 transcript structure indicates that
point mutations, translocations, and intragenic deletions of
SHANK3 found in ASD patients are isoform-specific. For
example, the intron 5 splicing mutations in the exon encoding
the ANK domain is only predicted to affect two long isoformsNeuron 78, April 10, 2013 ª2013 Elsevier Inc. 13
Figure 2. Shank Protein Interactions and
Isoform-Specific Domain Structure
(A) Schematic of the partial Shank protein inter-
actome at the PSD with Shank3 as a model. A
more complete list of Shank family interacting
proteins is shown in Table 2. Protein domains in
Shank family members are similar. Many inter-
acting proteins interact with all three Shank family
proteins (Shank1, Shank2, and Shank3) in in vitro
assays. The proteins in red font are altered in
Shank3 mutant mice.
(B) Diagram of SHANK3 protein isoforms
SHANK3a-f. Protein domain structure was
deduced from confirmed mRNAs expressed from
different promoters in human and mouse brains.
Polypeptides have not been validated due to the
lack of isoform-specific antibodies. Pro, proline-
rich region.
(C) Diagram of SHANK2 protein isoforms of
SHANK2A, 2B, 2C, and 2E (modified from Leblond
et al., 2012). SHANK2C has an alternative stop
codon due to the alternative splicing of exons 19
and 20 as shown in Figure 1B.
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SHANK3b) (Figures 1A and 2B). The intron 19 splicing mutation
will disrupt most isoforms but leave SHANK3f and other short
isoforms intact. Mutations in exon 21 are expected to have no ef-
fect on mRNAs lacking exon 21 or other short SHANK3 mRNAs
truncated before exon 21. Similarly, deletions within exons 1–9
and exons 1–17, and translocation breakpoints within intron 8
and exon 21, will affect different isoforms predicted from the
SHANK3 gene structure. In contrast, microdeletions or large
cytogenetic deletions will disrupt all SHANK3 isoforms. There-
fore, the molecular consequences at the RNA and protein levels
for each SHANK3 mutation are almost certainly different. A
determination of how different mutations and genetic variants
influence the array of potential Shank3 proteins awaits the
generation of isoform-specific antibodies.
If each Shank3 isoform has distinct functions at the synapse,
one attractive hypothesis is that isoform-specific disruption of
SHANK3 will result in different phenotypic consequences. This
may offer an explanation for the clinical heterogeneity in ASD
caused by SHANK3 mutations. A similar principle may be appli-
cable to ASD caused by defects in other genes. Consistent with
this notion, many known ASD genes, such as neuroligins and
neurexins, display a complex pattern of isoform-specific expres-
sion in brain (Boucard et al., 2005; Su¨dhof, 2008), with different
isoforms having very distinct functions (Chih et al., 2006). In
the cases of neurexins, more than 1,000 isoforms have been re-
ported (Missler and Su¨dhof, 1998).14 Neuron 78, April 10, 2013 ª2013 Elsevier Inc.The expression of Shank3 isoforms is
cell type-specific and developmentally
regulated (Lim et al., 1999; Maunakea
et al., 2010). RNA in situ hybridization in
rat brain using a single probe from exon
21 encoding the proline-rich domain
showed that Shank3 is widely expressed
in all brain regions at a low level at birth
but increases after 2 weeks of age in the
striatum, hippocampus, cerebellum, andin layers 1 and 2 of the neocortex (Bo¨ckers et al., 2001, 2004).
Similar findings were reported in mouse brain using a probe
from exon 21 encoding the proline-rich domain of mouse Shank3
(Pec¸a et al., 2011). Peak expression of Shank3 occurs at an
important developmental stage of synaptic plasticity and experi-
ence-dependent circuit maturation (Bo¨ckers et al., 2004). These
studies, however, have not defined the isoform-specific expres-
sion of Shank3, and thus the expression profile for different
Shank3 isoforms and regulation of isoform-specific expression
remain to be elucidated. To add further complexity, SHANK3
has five CpG islands across the gene and these CpG islands
display brain-specific and cell-type-specific DNA methylation
(Figure 1A; Beri et al., 2007; Ching et al., 2005; Maunakea
et al., 2010). Both DNA methylation and histone deacetylase in-
hibitors have been shown to modulate the isoform specific gene
expression of Shank3 in cultured neurons (Beri et al., 2007;
Maunakea et al., 2010). Thus, in addition to alternate promoter
use and mRNA splicing, epigenetic mechanisms such as DNA
methylation and histone acetylation regulate the expression of
the Shank3 gene in an isoform-specific manner. Multiple intra-
genic CpG islands are also associated with SHANK1 and
SHANK2 (Figures 1B and 1C), but the role of these CpG islands
in transcriptional regulation remains to be investigated.
SHANK2 exhibits transcriptional regulation similar to SHANK3
(Leblond et al., 2012). Specifically,SHANK2 has several isoforms
driven by multiple promoters and alternative splicing of coding
exons (Figure 1B). The longest Shank2e isoform containing all
Table 2. SHANK Family Interacting Proteins
Domain Direct Partner Function Select References
ANK a-fodrin, sharpin Actin-based cytoskeleton,
dendritic spine development
Bo¨ckers et al., 2001; Lim et al., 1999
SH3 GRIP1, Cav1.3, Densin-180 AMPA receptor trafficking, CREB, Wnt
signaling pathways, dendritic spine
remodeling, interaction with CaMKII
Quitsch et al., 2005; Sala et al., 2001;
Sheng and Kim, 2000; Uemura et al.,
2004; Zhang et al., 2005
PDZ GKAP1(SAPAP1), GKAP3(SAPAP3),
PSD-93, mGluR1/5, AMPA receptors,
b-PIX, ProSAPiP1, LASPER1,
ProSAPiP2, PLC-b3
Cytoskeleton, dendritic spine formation
and remodeling, synaptic transmission
and plasticity, self-multimeirzation
Gundelfinger et al., 2006; Kreienkamp,
2008; Liebau et al., 2009; Wendholt
et al., 2006
Proline-rich/Homer
and Cortactin binding
Homer1, Dynamin-2, Abp1, Abi1,
Cortactin, IRSp53
Arp 2/3 complex, regulation of
actin-based cytoskeleton, dendritic
spine formation and remodeling,
synaptic transmission and plasticity,
AMPA receptor endocytosis
Haeckel et al., 2008; Lu et al., 2007;
Okamoto et al., 2001; Proepper et al.,
2007; Qualmann et al., 2004; Soltau
et al., 2002, 2004; Tu et al., 1999
SAM Shank3 Synaptic targeting, self-multimerization,
Zn2+ binding
Baron et al., 2006; Boeckers et al.,
2005; Naisbitt et al., 1999
SHANK3 full-length
protein
ACTN2, CLU, GKAP1, GKAP3,
HNRNPC, LZTS3, PICK1, SYNGAP1
Shared interactions with PSD-95;
no functional studies described
Sakai et al., 2011
ANK, ankyrin repeat domain; SH3, Src homology 3 domain; PDZ, PSD-95/Discs large/ZO-1 domain; Pro, a proline-rich region containing homer- and
cortactin-binding sites; SAM, sterile alpha motif domain; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid.
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cific isoform in rat (McWilliams et al., 2004). However, a recent
report indicates that SHANK2E is also expressed in brain tissues
in humans (Leblond et al., 2012). Several short isoforms
(SHANK2A, SHANK2B, and SHANK2C) are transcribed from
downstream promoters (SHANK2A, SHANK2B) or result from
alternative splicing (SHANK2C) that contain distinct combina-
tions of protein domains (Figure 2C). Tissue-specific alternative
splicing of exons 19–20, exon 23, and an alternative stop codon
in exon 22 of SHANK2C have also been identified in humans
(Figure 1B; Leblond et al., 2012). The alternative splicing of exons
19-20 and isoforms of SHANK2E (Y.-h.J., unpublished data),
SHANK2A, and SHANK2B (Lim et al., 1999) were conserved in
mice but the status of SHANK2C and other spliced exons has
not been confirmed. Similar to SHANK3, the combination of
different promoters and splicing is expected to produce sub-
stantial protein diversity of SHANK2 that may carry out distinct
functions at synapses. Although similar complexity of transcrip-
tional structure has been suggested for SHANK1 (Figure 1C),
detailed transcript profiles related to alternative promoters and
exons remain to be delineated (Lim et al., 1999). Together, the
available evidence indicates that the overall transcriptional
structure of SHANK family genes is conserved in mice (Wang
et al., 2011). However, the complexity of transcriptional regula-
tion poses a significant technical challenge to adequately model
human SHANK mutations in mice.
Modeling SHANKs Mutations in Mice
Mutant mice for all Shank family genes have now been produced
and characterized (Figure 3). Shank1mutant mice with a deletion
of exons 14–15 encoding the PDZ domain were first reported in
2008 (Hung et al., 2008; Figure 3C), and more extensive behav-
ioral analyses were conducted subsequently (Silverman et al.,
2011; Wo¨hr et al., 2011). The targeted deletion of exons 14–15is believed to produce a null allele of Shank1. Because the tran-
script structure has not been fully characterized, the possibility
that this is not a complete Shank1 knockout cannot be ruled
out. The major molecular and behavioral phenotypes of Shank1
mutant mice are summarized in Table 3. The synaptic proteins
GKAP/SAPAP and Homer are reduced in the PSD of Shank1/
mouse brain. Smaller dendritic spines were observed, but the
ultrastructure of the PSD is unaffected at CA1 synapses of
Shank1/ mice. Basal synaptic transmission was reduced but
long-term potentiation (LTP) and long-term depression (LTD) in
CA1 hippocampus were unaffected (Hung et al., 2008). Behav-
ioral analyses revealed subtle impairments in social interaction
and communication aswell as increased repetitive behaviors (Sil-
vermanet al., 2011;Wo¨hr et al., 2011). Intriguingly, spatial learning
andmemorywasenhanced inShank1/mice (Hunget al., 2008).
Two different lines of Shank2mutant mice have been recently
reported (Schmeisser et al., 2012; Won et al., 2012). Schmeisser
et al. reported Shank2 exon 7 deletion mutant mice (Shank2
Dex7) while Won et al. described mice with both exons 6 and 7
deleted (Shank2 Dex6–7). Exons 6–7 encode the PDZ domain
of Shank2. Importantly, the exon numbering is defined based
on mouse Shank2a/ProSAP1a isoform cDNA (AB099695 or
NM_00111373). Full-length mouse Shank2 mRNA has not been
reported or deposited in a public database. Using the longest
rat cDNA of Shank2 deposited in GenBank (NM_201350) as a
reference, one can deduce that exons 6 and 7 in mouse Shank2a
isoform correspond to exons 16 and 17 of predicted full
length mouse Shank2 deduced from rat cDNA (NM_201350)
(Figure 3B). The difference in exon numbering for SHANK2 in
different organisms in other reports is likely due to the pattern
of uncharacterized exons or alternative splicing (Leblond et al.,
2012; Lim et al., 1999; McWilliams et al., 2004). The deletion of
exon 7 and exon 6-7 of Shank2a (exons 17 and exons 16–17 of
predicted full-length Shank2) resulted in a frame shift of theNeuron 78, April 10, 2013 ª2013 Elsevier Inc. 15
Figure 3. Targeted Mutations in Shank Genes in Mice
(A) Schematic of the mouse Shank3 gene structure deduced from cDNA AB230103 deposited in GenBank. The promoters are shown by arrows and alternatively
spliced exons are indicated in red. The exact transcription starting site of promoter 3 remains to be determined. The positions of targetedmutations in five different
(legend continued on next page)
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molecular nature of these two targeted mutations is predicted
to be very similar at protein level. Analyses of protein composi-
tion, synaptic development and function, and behaviors have
revealed similarity but also significant differences between these
two lines of Shank2 mutant mice (Table 3). Below, we utilize
the exon 6–7 nomenclature based on numbering from promoter
2 of Shank2a/ProSAP1a. Full-length exon numbering is depicted
in Figure 3B.
Biochemically, protein composition at synapses was altered
in both Shank2 Dex7 and Dex6–7 mice but with slight differ-
ences. In Shank2 Dex7/ mice, GluN1 and GluN2B NMDA-
type glutamate receptors in hippocampus and GluN1, GluN2A,
and GluA1 in striatum are increased (Schmeisser et al., 2012).
Interestingly, Shank3 was upregulated in striatum of Shank2
Dex7/ mice. In Shank2 Dex 6-7/ mice, reduction of phos-
phorylated CaMKIIa/b (T286), ERK1/2, p38, and GluA1
(S831/S845) was observed in hippocampus (Won et al., 2012).
Similar to Shank2 Dex7/ mice (Schmeisser et al., 2012),
GluN1 is increased in the hippocampus of Shank2 Dex6–7/
mice (Won et al., 2012). Whereas baseline synaptic transmission
was reduced in Shank2 Dex7/ mice (Schmeisser et al., 2012),
normal synaptic transmission was observed in Shank2
Dex6–7/ mice (Won et al., 2012). mEPSCs recorded from
CA1 hippocampal neurons were unaltered in Shank2 Dex6–7/
mice, but reduced in Shank2 Dex7/mice. Interestingly, the ra-
tio of NMDA/AMPA currents was reduced at CA1 synapses in
Shank2 Dex6–7/ mice but increased at the same synapses
of Shank2 Dex7/ mice. NMDA receptor-dependent LTP in
hippocampal CA1 synapses was increased and LTD was unaf-
fected in Shank2 Dex7/ mice. In contrast, both NMDA recep-
tor-dependent LTP and LTD at CA1 synapses were reduced in
Shank2 Dex6–7/ mice. Behaviorally, hyperactivity, impaired
social interaction, altered ultrasonic vocalizations, and increased
self-grooming were observed in both Shank2 Dex6–7/ and
Shank2 Dex7/ mice. Spatial learning and memory was
impaired in Shank2 Dex6–7/ but normal in Shank2 Dex7/
mice. The basis for apparent discrepancies in synaptic
physiology but similar behavioral profiles between Shank2
Dex6–7/ and Shank2 Dex7/ mice is not immediately clear
and further investigation is warranted. Interestingly, treatment
with D-cycloserine, an NMDA receptor agonist, restored the
NMDA/AMPA ratio and improved social interaction in the
three-chamber social interaction assay in Shank2 Dex6–7/
mice (Won et al., 2012). In addition, treatment with CDPPB,lines ofShank3mutantmice are shown. The transcripts from promoters upstream
transcripts from promoter downstream of deleted exons are predicted to be inta
isoform-specific expression of Shank3 mRNA and proteins in Shank3 mutant mic
remains intact. The full complement of Shank3 mRNA and protein isoforms that d
unknown. Therefore, the pattern of isoform-specific expression and disruption b
(B) Schematic of mouse Shank2 gene structure and mouse mutations of Shank2.
structure is deduced from a longest rat Shank2 cDNA deposited in GenBank
SHANK2E, SHANK2A, and SHANK2B are conserved in mice (Shank2e, Shank2a
mutations (exon numbering based on the sequences of Shank2a/ProSAP1A cD
shown (Schmeisser et al., 2012;Won et al., 2012). Exons 6 and 7 inShank2a are de
diagram. The Shank2a a Dex7 or Dex6–7 is predicted to cause truncation of all t
(C) Schematic of mouse Shank1 gene structure and mouse mutation of Shank1
(Shank1a and 1b in red arrows) (Hung et al., 2008).
In (A)–(C), genomic distance and exons are not drawn to scale.an mGluR5-selective positive allosteric modulator, not only
rescued the reduced NMDA/AMPA ratio but also recovered the
defective LTP and LTD in hippocampus as well as biochemical
changes in Shank2 Dex6–7/ mice. CDPPB also reversed
the impaired social interaction in Shank2 Dex6–7/
mice without affecting other behavioral impairments (Won
et al., 2012).
Five lines of Shank3 mutant mice carrying different mutations
in Shank3 have been reported (Bozdagi et al., 2010; Pec¸a et al.,
2011; Schmeisser et al., 2012; Wang et al., 2011; Figure 3A). The
mutations in these mice include deletions of exons 4–9 by two
groups with slightly different design (Dex4–9Buxbaum(B) [Bozdagi
et al., 2010] and Dex4–9Jiang (J) [Wang et al., 2011]), deletion of
exons 4–7(Dex4–7) (Pec¸a et al., 2011) encoding the ANK repeat
domain, deletion of exon 11(Dex11) encoding the SH3 domain
(Schmeisser et al., 2012), and deletion of exons 13–16 (Dex13–
16) encoding the PDZ domain (Pec¸a et al., 2011). Because all
of these deletions cause a frame shift for targeted transcripts,
they all resulted in either a truncated Shank3 protein or possible
disruption of full-length RNA or protein isoforms due to the
stability of encoded mRNA or protein. Based on current knowl-
edge ofShank3 promoters and alternative splicing, each of these
mice is expected to have disruption of different Shank3 isoforms
(Wang et al., 2011; Figure 3A). Isoform-specific disruption of
Shank3 was evident in Dex4–7, Dex4–9J, Dex11, and Dex13–
16 mice (Pec¸a et al., 2011; Schmeisser et al., 2012; Wang
et al., 2011). The Dex4–9J deletion disrupted mRNA transcripts
from promoters 1 and 2 (Shank3a and Shank3b) but not
Shank3c-f as confirmed by isoform-specific RT-PCR analysis
(Wang et al., 2011). One unexpected finding from RNA expres-
sion analysis of Dex4–9J mice was the presence of an mRNA
splice isoform from exon 2 to exon 10, in addition to the expected
splicing isoform from exon 3 to exon 10 due to the deletion of
exons 4–9 (Wang et al., 2011). Intriguingly, this cryptic splicing
from exon 2 to 10 occurred only in brain but not in kidney of
Dex4-9J/ mice. The mRNAs with joining of exons 2–10 and
exons 3–10 were stable and were predicted to result in a frame
shift in protein sequence shortly after exon 10. Whether the
same cryptic splicing occurs in the Dex4–9B mutant mice has
not been investigated (Bozdagi et al., 2010). Although targeted
deletion may interfere with pre-mRNA splicing mechanisms,
the basis for tissue specificity of cryptic splicing is unknown.
This observation adds to the complexity of predicting the molec-
ular consequence of different mutations in Shank3mutant mice,
and perhaps in human SHANK3 mutations, and suggests thatof deleted exons are predicted to be truncated or disrupted (red arrows) and the
ct in each mutant line of mice (black arrows). Bottom panels depict predicted
e. The ‘‘’’ indicates that the isoform is disrupted and ‘‘+’’ indicates the isoform
erive from combinations of alternative promoters and mRNA splicing remains
y specific mutations is likely more complex than indicated.
The sequence of Shank2 full-length mRNA is not available and the intron-exon
(NM_201350). Exons in red are alternatively spliced. The human isoforms of
, and Shank2b), but the status of SHANK2C is unknown. The Dex7 and Dex6-7
NAs NM_001113373 or AB099695) described in the Shank2 mutant mice are
duced to correspond to exons 16 and 17 in the full lengthShank2 gene structure
ranscripts of Shank2 from the promoters upstream of exons 6–7 (red arrows).
. The deletion of exons 14–15 is predicted to disrupt all isoforms of Shank1
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Table 3. Molecular, Biochemical, Synaptic, and Behavioral Phenotypes of Shank1 and Shank2Mutant Mice
Shank1 Shank2 Shank2
Reference Hung et al., 2008; Silverman et al.,
2011; Wo¨hr et al., 2011
Won et al., 2012 Schmeisser et al., 2012
Exons/domain targeted Exons 14–15/PDZ (Dex14-15) Exons 6–7/PDZ (Dex6-7 of Shank2a) Exon 7/PDZ (Dex7 of Shank2a)
Strain/background 129SvJ ES cell and backcrossing
to C57BL/6 for 3 generations
129SvJ ES cells and backcrossing
to C57BL/6 for >5 generations
129SvR1 ES cells and backcrossing
to C57BL/6J for 10 generations
Age of mice tested Biochemistry: 3 months
Morphology: E18 day for neuron
culture and adult mice
Electrophysiology: 3–5 weeks
Behavior: 3–5 months
Biochemical: 3–4 weeks
Morphology: 8–9 weeks
Electrophysiology: 3–9 weeks
Behaviors: 1–5 months
Biochemical: P25 and P70 days
Morphology: E18 neuron culture
and adult mice
Electrophysiology: P21, P27,
and 90 days
Behaviors: 6–8 months
Transcripts not disrupted Predicted to be none Predicted to be none Predicted to be none
Genotype of mice
analyzed
Homozygous, some
heterozygous
Homozygous, some heterozygous Homozygous, some heterozygous
Altered synaptic proteins Reduced GKAP and Homer Whole brain: Reduction of
p-CaMKIIa/b (Thr286), p-ERK1/2,
p-p38, p-GluA1(S831/S845),
increased GluN1
Hippocampus: Increased GluN2B
Striatum: Increased GluN1, GluN2A,
GluA2, SHANK3
Brain and synaptic
morphology
CA1 Hippocampus
Reduced spine density,
smaller and thinner PSD
CA1 Hippocampus
Normal spine density
No change in length and
thickness of PSD
CA1 Hippocampus
Reduced spine density, PSD
structure normal
Synaptic physiology CA1 Hippocampus
Reduced AMPAR-mediated
basal transmission.
Normal mEPSC amplitude.
Decreased mEPSC frequency.
Normal paired-pulse ratio.
Normal NMDA/AMPA ratio.
Normal LTP and LTD.
CA1 Hippocampus
No change in basal synaptic
transmission and normal mEPSC.
Reduced NMDA/AMPAR ratio.
Reduced NMDAR-dependent.
LTP and LTD. mGluR-dependent
LTD is normal.
Medial Prefrontal Cortex
Normal NMDA/AMPA ratio.
CA1 Hippocampus
Reduced synaptic transmission.
Reduced mEPSC frequency.
No difference for mEPSC amplitudes;
normal mIPSC frequency but slightly
reduced mIPSC amplitudes.
Normal sEPSC.
Increased NMDA/AMPA ratio.
Decreased I/O ratio.
LTP is slightly enhanced but LTD
is normal.
Social behaviors Reduced social sniffing
by males in male-female
interactions.
Reduced interest in novel mice
in nonsocial versus novel social
pairing in three chamber test.
Normal social recognition and
normal olfaction.
Normal initiation of social contact
but impairment in maintaining social
contact in resident-intruder test.
Impaired social interaction in three
chamber test. Normal olfaction.
Ultrasonic vocalizations Reduced calls by males
in male-female reciprocal
social interaction.
Male mice made less USV calls,
when females were presented
and had longer latency for
the first call.
Female pups made more USV calls.
No difference for USVs in adults during
male-male interaction but reduced
calls and longer latency during
female-female interaction.
Repetitive behaviors Increased self-grooming and
repetitive behaviors.
Increased locomotor activity.
No increased self-grooming in home
cage but increased in novel object
recognition task. Females show
repetitive jumping and reduced digging.
Increased self grooming/increased
locomotor activity.
Learning and memory Enhanced spatial learning and
memory task. Impaired fear
conditioning.
Impaired spatial and learning and
memory in Morris water maze. Novel
object recognition memory is normal.
Normal working memory. Novel
objective recognition memory.
Other behaviors Partial anxiety-like behavior.
Reduced scent-marking behaviors.
Increased anxiety-like behavior.
Impaired nesting behavior.
Increased anxiety-like behaviors.
AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; LTP, long-term potentiation; LTD, long-term depression; mEPSC, miniature excit-
atory postsynaptic current; mIPSC, miniature inhibitory postsynaptic current; NMDA, N-methyl-D-aspartate; I/O, input/output; mGluR5, metabotropic
glutamate receptor 5; USV, ultrasonic vocalization.
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Dex4–7 may have different molecular consequences for Shank3
at the mRNA and protein level. The Dex11 mutation (Schmeisser
et al., 2012) is predicted to disrupt promoters 1 to 3 for Shank3a-
c but not promoters 4 to 6 for Shank3d–f, while the Dex13–16
mutation (Pec¸a et al., 2011) is predicted to disrupt transcripts
from promoters 1 to 4 (Shank3a–d) but not from promoters 5 to
6 (Shank3e–f) (Figure 3A; Pec¸a et al., 2011), although this predic-
tion requires molecular confirmation. The effect on alternative
splicing of these targeted mutations has not been determined
and, as of yet, the full complement of Shank3 mRNA transcripts
and splice variants is not known and awaits characterization at
the mRNA and protein level. Beyond the mouse models, it will
be important to know the isoform expression of SHANK3 protein
in patients carrying various mutations if postmortem brain tissue
becomes available.
Phenotypic analyses at the biochemical, synaptic, and behav-
ioral levels were performed extensively on either heterozygotes
or homozygotes at different ages for Shank3 Dex4–7, Dex4–9J,
Dex4–9B, and Dex13–16, but to a lesser degree in Dex11 mutant
mice (Bozdagi et al., 2010; Pec¸a et al., 2011; Schmeisser et al.,
2012; Wang et al., 2011; Yang et al., 2012). The methods and
techniques used in these analyses were similar but not identical.
Different brain regions including hippocampus, striatum, and
neocortex were analyzed in different lines of mutant mice. Over-
all, the data obtained from these studies support a general
conclusion that synaptic function is impaired and social behav-
iors are abnormal in mice with Shank3mutations. In the following
sections, we compare and contrast phenotypes observed with
the various Shank3 mutant mice which are also summarized in
Table 4.
Synaptic Proteins in Shank3-Deficient Mouse Brain
PSD proteins were altered in different brain regions of all
Shank3mutant mice but to varying degrees in the hippocampus
of Dex4–9B+/, Dex4–9J/, and Dex11/; the striatum of
Dex11/ and Dex13–16/; and neocortex of Dex11/ mice.
Homer1b/c and GKAP1/SAPAP1 were reduced in the PSD frac-
tion but not in the cytosolic fraction of Dex4–9J/ hippocampus
(Wang et al., 2011). Homer1, GKAP/SAPAP, and PSD-93
were reduced in PSD fractions isolated from the striatum of
Dex13–16/ mice (Pec¸a et al., 2011) but GKAP/SAPAP was
not reduced in striatum of Dex11/ mice (Schmeisser et al.,
2012). Interestingly, Shank2 was increased in the synaptosomal
fraction of Dex11/ striatum, while Shank3 was found to be
increased in Shank2 Dex7/ mutant mice (Schmeisser et al.,
2012). This compensatory mechanism may contribute to the
reciprocal changes in Shank2 Dex7/ and Shank3 Dex11/
mice. It will be interesting to examinewhether the same phenom-
ena occurs in other Shank3mutant mice. Many of these proteins
were either not altered in the neocortex or not examined in
neocortex in these mutant mice. The corresponding changes
of Homer1 and Shank3 in several mouse lines and several brain
regions are consistent with the known multimeric network
formed between these two proteins (Hayashi et al., 2009; Tu
et al., 1999).
Mutations of Shank3 altered the levels of synaptic glutamate
receptors. The AMPA receptor subunit GluA1 was reduced inhippocampal neurons examined in culture and hippocampal tis-
sues from Dex4–9J/ (Wang et al., 2011) and Dex4–9B+/ mice
(Bozdagi et al., 2010), and GluA2 was reduced in the striatum of
Dex13–16/ mice (Pec¸a et al., 2011). In the case of NMDA re-
ceptors, GluN2A subunit was reduced in the hippocampus of
Dex4–9J/ mice (Wang et al., 2011). Both GluN2A and GluN2B
subunits were reduced in the striatum of Dex13–16/ mice
(Pec¸a et al., 2011), but they were unchanged in the stratum of
Dex11/ mice (Schmeisser et al., 2012). In contrast, GluN2B
was increased in synaptosomal fractions from Dex11/ hippo-
campus (Schmeisser et al., 2012). In nearly all mouse lines and
brain areas examined, changes in the level of these synaptic
proteins and receptors was relatively modest, and many other
known Shank3 interacting proteins listed in Table 2 were not
altered or not examined in mutant mice. The specific patterns
of altered synaptic proteins varied among different mutant
mice lines with similar mutations. Such variation may be due to
isoform-specific effects of different mutations. However, a direct
comparison, ideally by running the same experiments head-to-
head for each line of mutant mice with matched genotypes
and age, will be important for a quantitative comparison of the
effects of Shank3 mutations on synaptic protein composition at
synapses of different brain regions.
Synaptic Structure in Shank3 Mutant Mice
The ultrastructure of glutamatergic synapses was examined by
electron microscopy (EM) in all mutant mice except the
Dex4–9B+/ line. Decreased PSD thickness and length were
observed at corticostriatal synapses in Dex13–16/ mice
(Pec¸a et al., 2011), but not at hippocampal CA1 synapses in
ex4–9J/ mice (Wang et al., 2011) or Dex11/ mice
(Schmeisser et al., 2012). Dendritic branching and spine area
were increased in medium spiny neurons (MSNs) of the striatum
of Dex13–16/ mice (Pec¸a et al., 2011), but not examined in
striatum of mice carrying other Shank3 mutations (Pec¸a et al.,
2011; Schmeisser et al., 2012; Wang et al., 2011). Spine length
was increased in CA1 hippocampus of Dex4–9J/ mice
(Wang et al., 2011), and spine density was decreased in the stria-
tum and CA1 hippocampus of Dex13–16/ and Dex4–9J/
mice, respectively. The reduction of spine density visualized by
Golgi impregnation was developmental stage-specific in
Dex4–9J/mice, with significant spine loss observed at 4weeks
but not at 10 weeks of age (Wang et al., 2011). Activity-induced
spine growth by theta burst stimulation in cultured brain slices
was attenuated at CA1 synapses of Dex4–9B+/ mice (Bozdagi
et al., 2010).
The totality of ultrastructural and morphological analysis in
Shank3mutantmice indicates complex regulation of glutamater-
gic synapse size, shape, and structure. In general, mutation of
Shank3 leads to loss of spines, a reduction in spine volume,
and decreased PSD thickness in the adult. These effects,
together with spine elongation, suggests a phenotype of
reduced or delayed synapse maturation that is reminiscent of
the phenotypes observed inmousemodels of fragile X syndrome
(Comery et al., 1997; Irwin et al., 2001), Rett syndrome (Arm-
strong, 2005; Belichenko et al., 2009; Chao et al., 2007), and
Angelman syndrome (Dindot et al., 2008; Sato and Stryker,
2010; Yashiro et al., 2009). Notably, synapse structureNeuron 78, April 10, 2013 ª2013 Elsevier Inc. 19
Table 4. Molecular, Biochemical, Synaptic, and Behavioral Phenotypes of Shank3 Mutant Mice
Reference Bozdagi et al., 2010;
Yang et al., 2012
Wang et al., 2011 Pec¸a et al., 2011 Pec¸a et al., 2011 Schmeisser et al., 2012
Exons/domain
targeted
Exons 4–9B/ANK
repeat (Dex4–9B)
Exons 4–9J/ANK
repeat (Dex4–9J)
Exons 4–7/ANK
repeat (Dex4–7)
Exons 13–16/PDZ (Dex13–16) Exon 11/SH3 (Dex11)
Strain/background Bruce4 C57BL/6 ES cell
and maintain on C57BL/6
129SvEv ES cell backcrossing
to C57BL/6J for more than
6 generations
129SvR1 ES cell and
backcrossing to C57BL/6J
for one generation
129 SvR1 ES cells and
backcrossing to C57BL/6J
for more than 1 generations
129SvR1 ES cell and
backcrossing to C57BL/6
for more than 10 generations
Age of mouse Biochemistry: 3 months
Morphology: 3 months
Electrophysiology:3 months
Behaviors: P21 days to
16 weeks
Biochemistry: 3–4 months
Morphology: P1 neuron
culture and 1–3 months
Electrophysiology: 4–6 weeks.
Behaviors: 3–8 months
Biochemistry: not stated
Electrophysiology:
6–7 weeks
Behaviors: 5–6 weeks
Biochemistry: not stated
Morphology: 5 weeks
Electrophysiology: 5–7 weeks
Behaviors: 5–6 weeks
Biochemical: P25 and P70 days
Morphology: adult
Electrophysiology: N/A
Behaviors: N/A
Transcripts not
disrupted
Shank3c,d,e, f Shank3c,d,e,f Shank3c,d,e,f Shank3e, f Shank3d, e, f
Genotype of mice
analyzed
Heterozygous/homozygous Homozygous Homozygous Homozygous Homozygous
Altered synaptic
proteins
Reduction of GluA1 Reduction of GKAP,
Homer1b/c, GluA1, GluN2A
N/A Reduction of SAPAP3/GKAP3
Homer1, PSD-93, GluA2,
GluN2A, GluN2B
Increased GluN2B and Shank2
Brain and synaptic
morphology
CA1 Hippocampus
Activity-dependent spine
remodeling was affected,
CA1 Hippocampus
Longer dendritic spines.
Decreased spine density.
No change in length
and thickness of PSD.
N/A Striatum
Increase in striatal volume,
dendritic length, and surface a a.
Decreased spine density, leng
and thickness of PSD.
CA1 hippocampus
No defect identified.
Synaptic physiology CA1 Hippocampus
Reduced AMPAR-mediated
basal transmission.
Decreased mEPSC amplitude.
Increased mEPSC frequency.
Decrease in paired-pulse ratio.
Reduced LTP.
No change in NMDAR- or
mGluR-mediated LTD.
CA1 Hippocampus
No change in basal
synaptic transmission.
No change in amplitude
or frequency of mEPSCs
or mIPSCs.
No change in paired-pulse
ratio, I/O, fiber volley.
Reduced LTP.
Striatum
Slight reduction in
corticostriatal synaptic
transmission.
CA1 Hippocampus
No change in field recordings
population spikes, paired-puls
ratio, mEPSC frequency
and amplitude.
Striatum
No change in paired-pulse rat
Reduced field population spik
Reduced mEPSC frequency a
amplitude.
N/A
Social behaviors Reduced social sniffing
by males in male-female
interactions, mild social
impairment in reciprocal
interactions in juveniles.
Normal three chamber
test for adult mice.
Reduced interest in novel
mice in nonsocial versus
novel social pairing in three
chamber test, females
performed better than males.
Decreased bidirectional social
interactions in dyadic test.
Normal initiation of social
interaction. Perturbed
recognition of social
novelty during three
chamber test.
Perturbed recognition of socia
novelty during three chamber t.
Decreased reciprocal
interactions in dyadic test.
Decreased frequency of
nose-to-nose interaction.
Decreased anogenital sniffing
N/A
(Continued on next page)
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Reviewphenotypes vary with specific Shank3mutations, are different in
different brain regions, and display developmental heterogene-
ity, perhaps due to differential spatial and temporal expression
of other Shank family members or to compositional variation
across different populations of glutamatergic synapses.
Synapse Function and Plasticity in Shank3Mutant Mice
Shank proteins regulate the abundance and signaling of iono-
tropic glutamate receptors at excitatory synapses. Accordingly,
synaptic transmission and plasticity were examined in different
brain regions in all Shank3 except Dex11mutant mice. Measure-
ments of miniature excitatory postsynaptic current (mEPSC) fre-
quency and amplitude, paired pulse ratio, input/output (I/O)
curves, fiber volley, and population spikes indicated that synap-
tic transmission is reduced at hippocampal CA1 synapses of
Dex4–9B+/ (Bozdagi et al., 2010) and Dex4–9B/ (Yang et al.,
2012), but not in Dex4–9J/ (Wang et al., 2011) or Dex13–
16/ mice (Pec¸a et al., 2011), and was not examined in
Dex11/ mice (Schmeisser et al., 2012). The explanation for
the difference between Dex4–9B (Bozdagi et al., 2010; Yang
et al., 2012) and Dex4–9J (Wang et al., 2011) is not immediately
clear. One possibility is that these mutations induce different
cryptic splicing as described above in Dex4–9J/ mice (Wang
et al., 2011). Another possibility is that heterozygous mutations
may produce a dominant gain-of-function phenotype. In addi-
tion, mouse genetic background, animal age, and specific proto-
cols used for the studies may contribute to the variability.
In striatum, the frequency of mEPSCs and amplitude of popu-
lation spikes were significantly decreased in Dex13–16/ mice,
but only mildly affected in Dex4–7/ mice (Pec¸a et al., 2011).
Presynaptic responses measured by paired-pulse ratio and
input/output curves were not altered at corticostriatal synapses
in Dex13–16/ or Dex4–7/ mice (Pec¸a et al., 2011). The
different degree of synaptic transmission defects in mice with
specific Shank3 mutations supports the notion of an isoform-
specific contribution to synaptic function.
Hippocampal LTP was reduced at CA1 synapses of
Dex4–9J/and Dex4–9B but not examined in Dex11/ and
Dex13–16/ animals (Bozdagi et al., 2010; Pec¸a et al., 2011;
Schmeisser et al., 2012; Wang et al., 2011; Yang et al., 2012).
NMDA receptor-dependent long-term depression (LTD) induced
by low frequency stimulus and mGluR-dependent LTD induced
by PP-LFS were not affected in CA1 hippocampus of ex4–9B
mice (Bozdagi et al., 2010; Yang et al., 2012), suggesting an
alteration in the set-point for bidirectional Hebbian synaptic
plasticity (Cho and Bear, 2010). The same analysis was not
conducted in other mutant lines (Pec¸a et al., 2011; Wang et al.,
2011).
Collectively, these data support circuit defects mediated by
glutamate receptors in Shank3 mutant mice that appear to be
both synapse and mutation specific. It is not yet clear whether
there are common core synaptic defects in the various mutant
mice, but the phenotypic heterogeneity itself appears consistent
with the clinical heterogeneity of patients harboring SHANK3
mutations. Since different mutations affect different isoforms of
Shank3, some of the observed phenotypes may arise from iso-
form-specific effects on synaptic transmission. Firm conclusions
in this regard are complicated by the fact that the differentNeuron 78, April 10, 2013 ª2013 Elsevier Inc. 21
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ReviewShank3 isoforms are probably expressed in various Shank3
mutant mice, whichwere analyzed at different ages using slightly
different protocols. Moreover, acute knockdown of Shank3 in
cultured neurons decreases mGluR-dependent plasticity (Ver-
pelli et al., 2011), suggesting differences in effects of Shank3
on mGluR1/5 signaling over development and pointing to the
need for cautious interpretation regarding the pathogenic versus
compensatory roles of synaptic and circuit phenotypes
observed in Shank3 mutant mice.
Behavioral Phenotypes in Shank3 Mutant Mice
Based on the strong genetic evidence for SHANK3 defects as a
cause of human ASD, Shank3 mutant mice offer an opportunity
to model autism-like behaviors in rodents. Extensive behavioral
analyses were performed in Shank3 Dex4–9B(+/,/) (Bozdagi
et al., 2010; Yang et al., 2012), Dex4–9J/ (Wang et al., 2011),
Dex4–7/, and Dex13–16/ (Pec¸a et al., 2011) mutant mice
at different ages, on different genetic backgrounds, and using
different protocols. Themost notable and consistent observation
was reduced social interaction and affiliation behaviors using
different testing methods (Bozdagi et al., 2010; Pec¸a et al.,
2011; Wang et al., 2011; Yang et al., 2012). Variable perfor-
mances were noted in different cohorts of De4–9B/ mice
(Yang et al., 2012). Repetitive behaviors measured by increased
self-grooming in the home cage and behavioral inflexibility in
the reverse Morris water maze were observed in Dex4–9J/
(Wang et al., 2011) and Dex4–9B/ mice (Bozdagi et al., 2010;
Yang et al., 2012) but were not apparent in Dex4–7/ mice
(Pec¸a et al., 2011). A more marked increase in self-grooming
and self-injurious behaviors was observed in Dex11/ and
Dex13–16/ mice (Pec¸a et al., 2011; Schmeisser et al., 2012).
Different severity of similar behaviors with different mutations
may reflect Shank3 isoform-specific contributions to specific
behaviors. The number, frequency, and duration of ultrasonic
vocalizations were altered in a sex-specific manner in
Dex4–9J/ mice (Wang et al., 2011). Reduced ultrasonic vocal-
izations adult were also reported in Dex4–9B (Bozdagi et al.,
2010; Yang et al., 2012). The interpretation and predictive value
of aberrant ultrasonic vocalizations in mice relative to communi-
cation behaviors in human ASD remains the subject of investiga-
tion (Holy and Guo, 2005; Scattoni et al., 2009).
Despite the consistent intellectual disability reported in pa-
tients with multiple types of SHANK3 mutations, Shank3mutant
mice differed significantly in performance of learning and mem-
ory tasks. Impaired performance in the Morris water maze task
was seen in Dex4–9J/ mice (Wang et al., 2011) but not in
Dex13–16/ (Pec¸a et al., 2011) and Dex4–9B/ animals
(Yang et al., 2012). Short-term and long-term memory in a social
transmission test were impaired inDex4–9J/mice (Wang et al.,
2011). Prepulse inhibition (PPI) was not affected in Dex4–9J/
(Wang et al., 2011) and Dex4–9B/ (Yang et al., 2012) mice
but has not been examined in other mice.
Deciphering the relationship between phenotypic diversity
and themolecular diversity ofShank3mutations remains a signif-
icant challenge. It is tempting to speculate that the phenotypic
diversity in Shank3mutant mice reflects the clinical heterogene-
ity in patients with SHANK3 defects. In a strict sense, none of
these Shank3mousemutations are equivalent to SHANK3muta-22 Neuron 78, April 10, 2013 ª2013 Elsevier Inc.tions found in human ASD patients. The Dex4–9 (Bozdagi et al.,
2010; Wang et al., 2011) and Dex4–7 mutations in mouse (Pec¸a
et al., 2011) are closest to patients with intragenic exon 1–9 dele-
tion and splice mutation of intron 5 in SHANK3 (Bonaglia et al.,
2011; Hamdan et al., 2011; Table 1). Mutations in the SH3 and
PDZ domains are missense and splicing mutations in humans
(Boccuto et al., 2013; Waga et al., 2011), but mouse mutation
of Dex11 and Dex13–16 are exon deletion and frame shift muta-
tions (Pec¸a et al., 2011; Schmeisser et al., 2012).
Since each mutation has a different impact on Shank3 isoform
expression, a simple hypothesis is that the diversity of pheno-
types in Shank3 mutant mice reflects the molecular diversity of
Shank3. However, analysis of heterozygotes versus homozy-
gotes, different measurements in different brain regions, as well
as different genetic backgrounds could all contribute to pheno-
typic heterogeneity. Regarding genetic background, different
strains used included Bruce4 C57BL/6 (D4–9B) (Bozdagi et al.,
2010; Yang et al., 2012), mixed 129SvEv and C57BL/6J back-
crossed to C57BL/6J F7 generations (D4–9J) (Wang et al.,
2011), and mixed 129SvR1 and C57BL/6 background (Dex4–7,
Dex11, and Dex13–16) (Pec¸a et al., 2011; Schmeisser et al.,
2012; Table 4). A naturally occurring Disc1 (Disrupted in schizo-
phrenia) mutation in the 129 strain of ES cells (Clapcote et al.,
2007; Clapcote and Roder, 2006) was segregated from the
Dex4–9J/ deletion (Wang et al., 2011) but was not reported in
other Shank3 mutant mice using mouse 129 ES cells (Pec¸a
et al., 2011; Schmeisser et al., 2012). Synaptic dysfunction and
abnormal behaviors have been documented in mice harboring
Disc1 mutations (Clapcote et al., 2007; Kim et al., 2009), and
this may present a confounding factor for phenotypic analysis.
Translation of Shank Mutant Mice to Human ASD
It is a big leap frommouse behavioral phenotypes to human clin-
ical presentations of neurobehavioral disorders like ASD (Bucan
and Abel, 2002; Moy et al., 2006; Silverman et al., 2010). In hu-
man patients, ASD is a behavioral diagnosis with considerable
clinical heterogeneity. There is currently no reliable biomarker,
pathology, anatomical finding, or functional neuroimaging
change that can be considered pathognomonic or predictive
for ASD (Anagnostou and Taylor, 2011; Bauman and Kemper,
2005; Courchesne et al., 2007; Lord et al., 2000a). Remarkably
little is known about the neurological basis of ASD, and many
brain regions and circuits have been implicated in ASD (Amaral
et al., 2008; Anagnostou and Taylor, 2011; Bauman and Kemper,
2005; Courchesne et al., 2007). Several competing hypotheses
have been proposed to account for core deficits and ancillary
symptomatic domains in ASD, but none have been widely
accepted (Belmonte et al., 2004; Courchesne et al., 2007;
Geschwind and Levitt, 2007; Rubenstein, 2010; Zoghbi, 2003).
Because of the molecular and clinical heterogeneity docu-
mented in ASD, the challenge of interpreting any human data
from heterogeneous patient populations is obvious. In mouse
behavioral studies, testing paradigms for learning and memory
have been widely accepted (Crawley, 2008; Crawley and Paylor,
1997; Morris, 1981). However, to date none of the various social
and communication behaviors have been validated as robustly
translatable from rodents to humans (Silverman et al., 2010).
This may be due to the high degree of specialization and diverse
Neuron
Reviewstrategies for ethologically relevant social behaviors in mam-
mals, particularly primates (Bucan and Abel, 2002; Flint and
Mott, 2008; Kas et al., 2007). Although the triad of impaired social
interaction, language/communication, and stereotypical behav-
iors is recognized as core to ASD, the clinical presentation of
these impairments is highly varied in humans. In fact, there are
few clinical tools available to evaluate behavioral features quan-
titatively in humans that could guide more basic neurobiological
studies in model systems (Lord et al., 1994, 2000b, 2001).
A burning issue in the field is the extent to which common
pathophysiology underlies ASD. Analyses of the Shank mutant
mice indicate that subtle differences in mutations within a given
ASD risk gene can produce overlapping but non-identical
cellular, synaptic, and behavioral phenotypes. One approach
for the future will be to tailor specific Shank mutations in the
mouse to correspond precisely to human mutations where
patients have undergone extensive clinical evaluation. Another
important element for translating observations from Shank3
mutant mice will be to couple in vivo physiology and imaging in
the mouse to functional neuroimaging in human patients to
help identify conserved circuit phenotypes. Perhaps most signif-
icantly, the successful development of pharmacological thera-
pies for core clinical features of ASD would open the door to
more comprehensive data-driven validation of mouse models
to better enable forward translation.
Future Directions
Numerous questions have emerged from the analysis of SHANK
defects in human ASD patients and Shank mutant mice. In hu-
man patients, natural history studies of genotype and phenotype
in patients with various SHANKmutations are critical. A detailed
description and comparison of clinical features in patients with
mutations in different SHANK genes will provide guidance for
modeling human disease in animal models. Because of the
similar protein domain structure among SHANK family proteins,
it will be interesting to determinewhether ASD patients with anal-
ogous mutations in SHANK genes have significant overlapping
clinical features or whether different SHANK family members in-
fluence distinct phenotypes. At the molecular level, it will be
important to know the full complement of SHANK1, SHANK2,
and SHANK3 isoforms and how various ASD-linked mutations,
particularly point mutations or intragenic deletions, alter
SHANK2 and SHANK3 isoform expression in humans. To date,
most of the expression and subcellular localization data for
Shank3 have used a single RNA probe and single antibody which
may fail to detect differences among Shank3 isoforms.
There is a critical need to directly compare the different
Shank2 and Shank3 mutant mice head to head for cellular,
synaptic, circuit, and behavioral phenotypes. Such direct com-
parisons will allow for more definitive identification of common
synaptic defects, circuit endophenotypes, and behaviors. Can
mutations in Shank2 and Shank3 open the door to a molecular
pathway that provides novel therapeutic targets? Study of
Shank2 Dex6-7 mice has offered a promising start (Won et al.,
2012). For example, it will be important to examine whether
NMDA receptor agonists and mGluR5 positive allosteric modu-
lators reverse phenotypes in Shank2 Dex7/ mice (Schmeisser
et al., 2012) or in other Shankmutant mice. Perhaps more impor-tantly, the diverse and often noncongruent phenotypes in various
Shank mutant mice highlight the fact that most of the current
mouse models do not carry the human mutations. Specific
mutations are likely to produce specific phenotypes in patients
and hence must be modeled accordingly in mice for the mutant
mice to have full translational potential. Much remains to be
learned, but it is tempting to consider SHANK3 ‘‘restoration’’ in
a loose sense as a therapeutic strategy for Phelan-McDermid
syndrome, and perhapsmore broadly in ASD. Yet, anthropomor-
phizing rodent behavior in the hope of analogizing with symp-
tomatic improvement in neuropsychiatric disease is fraught
with cautionary tales. Interventions that improve cognitive per-
formance, behaviors, or neuropathology in rodents have
frequently not led to accelerated therapeutic development,
most notably in Alzheimer’s disease where reports abound of
cured mouse models despite repeated clinical failures (Cisse´
et al., 2011; Gandy and DeKosky, 2013; Malenka and Malinow,
2011; Vaillend et al., 2002). Ultimately, the value of Shankmutant
mice will depend critically on the ability to use human patients
to validate their predictive utility. Recently, whole genome
sequencing technology has successfully identified a list of candi-
date genes in ASD (Bi et al., 2012; Chahrour et al., 2012; Iossifov
et al., 2012; Neale et al., 2012; O’Roak et al., 2011; Sanders et al.,
2012), and this list will likely expand in the future. Because of the
rarity of sequence variants across the population, it has been
challenge to establish a causal role for specific variants in human
disease. Functional studies are thus a critical component to
determine the pathogenicity of specific genetic variants. The
lesson learned from modeling SHANK mutations in mice will
almost certainly be valuable to modeling other ASD candidate
genes in the future.
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